twentyfirst
centuri
seen
emerg
sever
rna
virus
caus
sever
infect
human
like
sar
mer
coronaviru
recent
ebola
viru
zika
viru
zikv
problem
emerg
viru
infect
lack
avail
medic
countermeasur
includ
antivir
treatment
therefor
develop
broadli
act
antivir
compound
well
screen
exist
drug
potenti
repurpos
explor
way
fasttrack
drug
develop
pipelin
emerg
viral
diseas
briefli
discuss
avail
inform
potenti
antivir
treatment
zikv
infect
well
specif
challeng
regard
use
antivir
zika
viru
positivesens
singlestrand
rna
arboviru
belong
genu
flaviviru
famili
flavivirida
base
nucleotid
sequenc
zikv
divid
african
lineag
asian
lineag
main
vector
zikv
transmiss
aed
mosquito
first
isol
zikv
made
serum
febril
rhesu
monkey
zika
forest
uganda
twentieth
centuri
sporad
human
case
zikv
infect
report
africa
caus
african
lineag
asia
caus
asian
lineag
epidemiolog
zikv
chang
dramat
last
decad
major
outbreak
asian
lineag
zikv
report
island
yap
french
polynesia
subsequ
asian
lineag
zikv
spread
america
twentyfirst
centuri
seen
emerg
sever
rna
virus
caus
sever
infect
human
like
sar
mer
coronaviru
recent
ebola
viru
zika
viru
zikv
problem
emerg
viru
infect
lack
avail
medic
countermeasur
includ
antivir
treatment
therefor
develop
broadli
act
antivir
compound
well
screen
exist
drug
potenti
repurpos
explor
way
fasttrack
drug
develop
pipelin
emerg
viral
diseas
briefli
discuss
avail
inform
potenti
antivir
treatment
zikv
infect
well
specif
challeng
regard
use
antivir
zika
viru
positivesens
singlestrand
rna
arboviru
belong
genu
flaviviru
famili
flavivirida
base
nucleotid
sequenc
zikv
divid
african
lineag
asian
lineag
main
vector
zikv
transmiss
aed
mosquito
first
isol
zikv
made
serum
febril
rhesu
monkey
zika
forest
uganda
twentieth
centuri
sporad
human
case
zikv
infect
report
africa
caus
african
lineag
asia
caus
asian
lineag
epidemiolog
zikv
chang
dramat
last
decad
major
outbreak
asian
lineag
zikv
report
island
yap
french
polynesia
subsequ
asian
lineag
zikv
spread
america
current
outbreak
zikv
show
new
mode
transmiss
mothertofetu
transmiss
sexual
transmiss
furthermor
infecti
zikv
detect
breast
milk
concern
zikv
transmiss
blood
product
obtain
asymptomat
virem
person
organ
transplant
postnat
acquir
zikv
infect
asymptomat
associ
mild
symptom
recent
outbreak
brought
two
sever
complic
light
guillainbarrelik
syndrom
gb
associ
paralysi
microcephali
neurodevelopment
problem
infant
born
women
infect
zikv
pregnanc
rate
complic
estim
around
case
gbslike
syndrom
may
consider
higher
teratogen
effect
although
much
remain
unknown
precis
extent
possibl
sequela
fetus
infant
signific
contribut
factor
knowledg
gap
zika
viru
infect
may
asymptomat
silent
infect
women
potenti
affect
fetus
babi
may
go
unnot
current
drug
approv
treatment
sever
nucleosid
analogu
drug
antivir
activ
cell
cultur
nucleosid
like
ribavirin
favipiravir
fig
addit
show
modest
antizikv
activ
mice
ribavirin
favipiravir
alreadi
approv
use
antivir
drug
human
indic
show
less
vitro
antivir
effect
zikv
initi
develop
treatment
hepat
c
viru
hcv
distantli
relat
zikv
studi
shown
compound
activ
flavivirus
much
close
relat
zikv
like
dengu
viru
denv
interest
antihcv
nucleosid
analogu
like
approv
sofosbuvir
mericitabin
clinic
trial
also
show
vitro
activ
denv
two
broad
spectrum
antirna
viru
nucleosid
analogu
current
phase
clinic
trial
accord
manufactur
reduc
mortal
zikvinfect
mice
data
yet
publish
show
evid
use
broad
spectrum
antivir
drug
zikv
particular
broad
spectrum
nucleosid
analogu
level
evid
thu
far
insuffici
licens
clinic
applic
also
major
challeng
antivir
treatment
would
appli
avail
drug
activ
cell
nervou
system
cross
bloodbrainbarri
placenta
safe
pregnant
women
fetus
infant
mean
trivial
concern
exampl
unfavor
toxic
profil
ribavirin
includ
teratogen
limit
use
treat
zikv
infect
pregnant
women
addit
lesson
learn
treat
rna
virus
monotherapi
caus
rapid
emerg
resist
virus
stress
need
develop
drug
differ
mode
action
reduc
likelihood
select
resist
strain
given
time
need
develop
approv
new
antivir
drug
clinician
current
left
empti
hand
term
target
antivir
treatment
zikv
infect
major
lesson
outbreak
previou
emerg
rna
viru
outbreak
need
safe
broad
spectrum
antivir
drug
test
rapidli
phase
iii
clinic
trial
outbreak
gain
time
need
develop
control
prevent
measur
particularli
vaccin
